Healthcare

The healthcare industry welcomed the guidelines issued by the Central government that assured sops such as land, clearances, tax breaks and funding to set up hospitals in tier 2 and tier 3 cities, to support Pradhan Mantri Jan Arogya Yojana…

The growth trajectory of global pharma industry will benefit from several technological advances transforming healthcare as we know it. Undeniably, cell and gene therapy are becoming more tangible as breakthrough therapy options with…

Domestic Context - Supportive policy changes needed across the cross-section Invigorating policy framework to re-create the API backbone -One of the burning challenges in the Indian landscape that needs urgent attention is bleak API…

Pushpa Vijayaraghavan, Director, Sathguru Management Consultants, predicts that pharma in 2019 will be a mixed landscape of transformational innovation, value chain shifts and tapered growth with continued pricing pressure Most regional…

New Delhi: We are all set to welcome a brand new year 2019, energized and full of fresh ideas. The freshness of new year is always marked by the expectations galore. There is always a repeat of wish lists out of which few get fulfilled…

Sathguru’s Healthcare Practice Lead Pushpa Vijayaraghavan moderated the panel on “Indian Bulk Drug Industry- Regaining the Lost Glory” at the CII National Pharmaceutical Conclave 2018 held in New Delhi on the 19th of November. The session…

Sathguru’s Healthcare Practice Lead Pushpa Vijayaraghavan moderated the panel on “Current state of biosimilars and prospects for the future” at the CII National Biotech Conclave 2018 held in New Delhi on the 22nd of November. The session…

The Report can be downloaded at Indian Biosimilars Industry Biosimilars present a very attractive opportunity for Indian pharma companies going beyond small molecule generics ridden with intense competition and price pressures. With record…

Pushpa Vijayaraghavan is confident that Indian companies will continue to be the most dominant contributor in the global public health landscape. Indian vaccine manufacturers contribute to 76 percent of UNICEF tender volumes and the top…

Our experts conclude: ‘From a consumer perspective, it is encouraging to see proactive regulatory action in the interest of patient safety and benefit. However, with blanket decisions underlined by redundancy in action, patients could be…